Therapy with non-steroidal anti-inflammatory drugs and the quality of life of patients with rheumatic diseases
https://doi.org/10.14412/1996-7012-2022-1-103-107
Abstract
The modern strategy for the treatment of rheumatic diseases (RD) involves the fastest possible achievement of remission or low disease activity. However, even with the use of the most modern technologies and after a pronounced decrease in the inflammatory activity of the disease, it is not always possible to achieve a complete and stable remission. In such a situation, an important goal of treatment is to maximize the quality of life (QoL) of patients. Pain is one of the leading predictors of a decrease in QoL in patients with RD. At the same time, effective pain control can improve not only the course of individual symptoms of the disease, but also life prognosis as a whole. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most popular drugs for the symptomatic treatment of RD. At the same time, the administration of NSAIDs with a favorable safety profile can improve the quality of life of patients. Meloxicam is the first predominantly selective inhibitor of cyclooxygenase (COX) 2, which appeared in the arsenal of practitioners in the late 90s and has a strong evidence base for efficacy and safety.
Keywords
Supporting agencies: This article has been supported by Boehringer Ingelheim.
About the Authors
E. Yu. Polishchuk
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
Elena Yurievna Polishchuk
34A, Kashirskoe shosse, Moscow 115522
A. E. Karateev
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
V. N. Amirdzhanova
V.A. Nasonova Research Institute of Rheumatology
Russian Federation
Russian Federation
34A, Kashirskoe shosse, Moscow 115522
References
1. Nasonov EL, editor. Rossiiskie klinicheskie rekomendatsii. Revmatologiya [Russian clinical guidelines. Rheumatology]. Moscow: GEOTAR-Media; 2020. 448 p.
2. Lila AM, Alekseeva LI, Taskina EA. Modern approaches to the treatment of osteoarthritis taking into account the updated international recommendations. Russkii meditsinskii zhurnal. 2019;3(11):48-52. (In Russ.).
3. Pincus T, Castrejon I, Yazici Y, et al. Osteoarthritis is as severe as rheumatoid arthritis: evidence over 40 years according to the same measure in each disease. Clin Exp Rheumatol. Sep-Oct 2019;37 Suppl 120(5):7-17. Epub 2019 Oct 14.
4. Amirdzhanova VN, Goryachev DV, Korshunov NI, et al. Population indicators of quality of life according to the SF-36 questionnaire (results of the multicenter study of quality of life «MIRAGE»). Nauchcno-Prakticheskaya Revmatologia. 2008;46(1):36-48. (In Russ.).
5. Sprangers MA, de Regt EB, Andries F, et al. Which chronic conditions are associated with better or poorer quality of life? J Clin Epidemiol. 2000 Sep;53(9):895-907. doi: 10.1016/s0895-4356(00)00204-3.
6. Anyfanti P, Triantafyllou A, Panagopoulos P, et al. Predictors of impaired quality of life in patients with rheumatic diseases. Clin Rheumatol. 2016 Jul;35(7):1705-11. doi: 10.1007/s10067-015-3155-z. Epub 2015 Dec 23.
7. Cleveland RJ, Nelson AE, Callahan LF. Knee and hip osteoarthritis as predictors of premature death: a review of the evidence. Clin Exp Rheumatol. Sep-Oct 2019;37 Suppl 120(5):24-30. Epub 2019 Oct 14.
8. Park D, Kwon Y. Factors Affecting Quality of Life and Satisfaction in Patients with Arthritis after Change to a Fixed-Dose Naproxen/Esomeprazole Combination Drug. Clin Orthop Surg. 2020 Mar;12(1):86-93. doi: 10.4055/cios.2020.12.1.86. Epub 2020 Feb 13.
9. Bai S, Guo W, Feng Y, et al. Efficacy and safety of anti-inflammatory agents for the treatment of major depressive disorder: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2020 Jan;91(1):21-32. doi: 10.1136/jnnp-2019-320912. Epub 2019 Oct 28.
10. Steffen А, Holstiege J, Klimke K, et al. Patterns of the initiation of disease-modifying antirheumatic drugs in incident rheumatoid arthritis: a German perspective based on nationwide ambulatory drug prescription data. Rheumatol Int. 2018 Nov;38(11):2111-20. doi: 10.1007/s00296-018-4161-7. Epub 2018 Oct 10.
11. Black RJ, Richards B, Lester S, et al. Factors associated with commencing and ceasing opioid therapy in patients with rheumatoid arthritis. Semin Arthritis Rheum. 2019 Dec; 49(3):351-7. doi: 10.1016/j.semarthrit.2019.06.003
12. Kimsey L, Weissman JS, Patel A, et al. Delay in initiation of DMARD or anti-inflammatory therapy in patients newly diagnosed with rheumatoid arthritis: An analysis of United States Military Health System TRICARE beneficiaries. Semin Arthritis Rheum. 2019 Apr;48(5):821-7. doi: 10.1016/j.semarthrit.2018.07.003.
13. Fidahic M, Jelicic Kadic A, Radic M, Puljak L. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev. 2017 Jun 9;6(6): CD012095. doi: 10.1002/14651858.CD012095.pub2.
14. Kvien T, Greenwald M, Peloso P, et al. Do COX-2 inhibitors provide additional pain relief and anti-inflammatory effects in patients with rheumatoid arthritis who are on biological disease-modifying anti-rheumatic drugs and/or corticosteroids? Post-hoc analyses from a randomized clinical trial with etoricoxib. Randomized Controlled Trial. BMC Musculoskelet Disord. 2015 Feb 13;16:26. doi: 10.1186/s12891-015-0468-7.
15. D'Angelo S, Gilio M, D'Attino RM, et al. Observational study on the QUality of life of Italian Axial SpondyloARthritis patients (QUASAR): baseline data. Clin Exp Rheumatol. 2019;37(5):748-55. Epub 2019 Apr 2.
16. Nassonova VA. Meloxicam (Movalis) – is a selective COX-2 inhibitor in clinical practice. Nauchcno-Prakticheskaya Revmatologia. 2000;(4):16-21. (In Russ.).
17. Nasonov EL, Tsvetkova ES. Selective inhibitors of cyclooxygenase-2: new perspectives of human diseases management. Terapevticheskii arkhiv. 1998;(5):8-14. (In Russ.).
18. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam com-pared diclofenac in osteoarthritis patients. International MELISSA Study Group. Meloxicam Large-scale International Study Safety Assessment. Br J Rheumatol. 1998 Sep;37(9):937-45. doi: 10.1093/rheumatology/37.9.937.
19. Dequerker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of selective cyclooxyenase (COX)-2 inhibitor, meloxicam, compared with piroxicam: results of the Safety and Efficacy Large Scale Evaluation of COX inhibiting Therapies (SELECT) trial in osteoarthritis. Br J Rheumatol. 1998 Sep;37(9):946-51. doi: 10.1093/rheumatology/37.9.946.
20. Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999 Dec 13;107(6A):48S-54S. doi: 10.1016/s0002-9343(99)00367-8.
21. Yang M, Wang HT, Zhao M, et al. Network Meta-Analysis Comparing Relatively Selective COX-2 Inhibitors Versus Coxibs for the Prevention of NSAID-Induced Gastrointestinal Injury. Medicine (Baltimore). 2015 Oct;94(40):e1592. doi: 10.1097/MD.0000000000001592.
22. Asghar W, Jamali F. The effect of COX-2-selective meloxicam on the myocardial, vascular and renal risks: a systematic review. Inflammopharmacology. 2015 Feb;23(1):1-16. doi: 10.1007/s10787-014-0225-9. Epub 2014 Dec 17.
23. Arfe A, Scotti L, Varas-Lorenzo C, et al. Non-steroidal anti-inflammatory drugs and risk of heart failure in four European countries: nested case-control study. BMJ. 2016 Sep 28;354:i4857. doi: 10.1136/bmj.i4857.
24. Schink T, Kollhorst B, Varas Lorenzo C, et al. Risk of ischemic stroke and the use of individual non-steroidal anti-inflammatory drugs: A multi-country European database study within the SOS Project. PLoS One. 2018 Sep 19;13(9):e0203362. doi: 10.1371/journal.pone.0203362. eCollection 2018.
25. Masclee GMC, Straatman H, Arfи A, et al. Risk of acute myocardial infarction during use of individual NSAIDs: A nested casecontrol study from the SOS project. PLoS One. 2018 Nov 1;13(11):e0204746. doi: 10.1371/journal.pone.0204746.eCollection 2018.
26. Karateev AE, Nasonov EN. Meloxicam in Russia: 20 years together. Terapevticheskii arkhiv. 2016;(12):149-58. (In Russ.).
27. Karateev AE, Nasonov EL, Pogozheva EYu, et al. An old friend: 25 years of meloxicam use in Russia. Nauchcno-Prakticheskaya Revmatologia. 2021;59(3):302-15 (In Russ.).
28. Karateev AE, Lila AM, Pogozheva EY, et al. The efficacy of meloxicam in acute back pain: results of an observational non-interventional multicenter study. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2018;118(6):24-30. (In Russ.).
29. Karateev AE, Lila AM, Zagorodni NV, Pogozheva EYu. Damage to periarticular soft tissues in real clinical practice: frequency, nature, effectiveness of non - steroidal anti - inflammatory drugs. Terapevticheskii arkhiv. 2019;91(12):21-8. (In Russ.).
30. Karateev AE, Lila AM, Zagorodnii NV, et al. Control of pain in the early post-traumatic period in the outpatient practice. Results of the multi-center observational study RAPTOR (Rational Analgesia PostTraumatic: an Observational Research). Terapevticheskii arkhiv. 2020;92(5):69-77. (In Russ.).
31. Karateev AE, Pogozheva EYu, Filatova ES, Amirdzhanova VN. Endoscopic picture of the upper gastrointestinal tract against the background of taking various NSAIDs. Klinicheskaya farmakologiya i terapiya. 2018;27(4): 40-5. (In Russ.).
Review
For citations:
Polishchuk EY, Karateev AE, Amirdzhanova VN. Therapy with non-steroidal anti-inflammatory drugs and the quality of life of patients with rheumatic diseases. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2022;16(1):103-107. (In Russ.) https://doi.org/10.14412/1996-7012-2022-1-103-107
Views:
727
Email this article 